L.A. area cardiologists leverage AI-enabled approach to develop personalized heart care diagnoses and treatment plans
Denver – May 3, 2023 -- Cleerly, the company creating a new standard of care for heart disease, today announced a partnership with Apex Cardiology to address the growing heart disease epidemic. Apex Cardiology is a recognized cardiology services leader in Los Angeles with nationally recognized cardiologists committed to exploring the use of new technologies and techniques. The company will use Cleerly’s AI-enabled approach to evaluating coronary computed tomography angiography (CCTA) imaging, allowing its cardiologists to more easily identify, characterize and qualify atherosclerosis (plaque) buildup in the walls of heart arteries.
“We are excited to partner with the Apex Cardiology team who are dedicated to improving the cardiovascular health of their community,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “Together, we are improving heart health through a personalized and precision approach to evaluating patients’ coronary artery disease risk.”
The information provided in Cleerly’s CCTA analysis promotes a more accurate understanding of a patient’s risk of heart attack and a marked shift from the way that heart disease has been historically assessed using indirect surrogate markers of heart disease. These surrogates often fail patients as predictors and miss the majority of patients who will suffer a heart attack. More than half of all patients who experience a heart attack show no symptoms or surrogate markers before their potentially catastrophic events.
This partnership will allow Apex Cardiology to access Cleerly’s comprehensive technology-enabled care pathway to care for patients across the entire continuum of disease presentation – from early diagnosis of heart disease to ensuring that ongoing treatments are effective for those who have elevated risk of symptoms.
“Cleerly allows us to obtain detailed information about the coronary arteries, which until recently, was only available by an invasive coronary angiogram,” said Dr. Mason Weiss, an interventional cardiologist serving patients at Apex Cardiology. “This partnership will allow us to determine the presence of coronary artery disease and inform personalized treatment that can help prevent heart attacks.”
Cleerly’s services are now available at Apex Cardiology and those interested can visit https://www.apexcardiology.com/contact-us/ to learn more and schedule an appointment.
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
For more information, please visit: https://www.cleerlyhealth.com.
Download: JPG |
Cleerly: March 26, 2024
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly: March 5, 2024
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
Cleerly: February 22, 2024
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Cleerly
